Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
暂无分享,去创建一个
[1] G. Dusheiko,et al. Current treatment of hepatitis B , 2007, Gut.
[2] Y. Liaw,et al. Chronic hepatitis B: treatment alert , 2006 .
[3] I. Sheen,et al. Emergence and takeover of precore‐stop mutant prior to exacerbation of e antigen‐negative chronic hepatitis B after withdrawal of lamivudine therapy , 2006, Journal of medical virology.
[4] Ding-Shinn Chen,et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. , 2006, The Journal of infectious diseases.
[5] Y. Liaw,et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[6] A. Lok,et al. Sustained response after a 2‐year course of lamivudine treatment of hepatitis B e antigen‐negative chronic hepatitis B , 2004, Journal of viral hepatitis.
[7] E. Keeffe,et al. Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.
[8] D. Lavanchy,et al. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.
[9] Y. Liaw,et al. Short-Term Lamivudine Therapy in Patients with Chronic Hepatitis B , 2003, Intervirology.
[10] C. Chu,et al. Determinants for sustained HBeAg response to lamivudine therapy , 2003, Hepatology.
[11] Y. Liaw. Therapy of chronic hepatitis B: current challenges and opportunities , 2002, Journal of viral hepatitis.
[12] M. Manns,et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. , 2002, Virology.
[13] M. Swain,et al. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. , 2001, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[14] R. Schinazi,et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.
[15] Y. Liaw,et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.
[16] C. Chu,et al. Clearance of the original hepatitis B virus YMDD‐motif mutants with emergence of distinct lamivudine‐resistant mutants during prolonged lamivudine therapy , 2000, Hepatology.
[17] C. Chu,et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.
[18] N. Leung,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.
[19] J. Cullen,et al. Lamivudine therapy of WHV-infected woodchucks. , 1998, Virology.
[20] J. Wands,et al. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.
[21] W. Mason,et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus , 1997, Journal of virology.
[22] D. Tyrrell,et al. Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo , 1996, Hepatology.
[23] E. Schiff,et al. A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.
[24] F. Beland,et al. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3'-azido-2',3'-dideoxythymidine. , 1994, Cancer research.
[25] V. Skalski,et al. Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. , 1992, The Journal of biological chemistry.
[26] R. Schinazi,et al. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[27] O. Yokosuka,et al. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. , 1991, The New England journal of medicine.
[28] G. Fattovich,et al. Natural history and prognostic factors for chronic hepatitis type B. , 1991, Gut.
[29] C. Chu,et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. , 2008, Liver.
[30] R. Beasley. Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.
[31] C. Chu,et al. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study , 1988, Hepatology.